To appraise the clinical and cost effectiveness of nivolumab in combination with platinum-doublet chemotherapy within its marketing authorisation for untreated PD-L1-negative non-small-cell lung cancer.
Following on from information provided to NICE by the company in August 2019, the appraisal of Nivolumab in combination with platinum-doublet chemotherapy for untreated non-small-cell lung cancer [ID1135] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 1135

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
08 November 2022 Discontinued. Following on from information provided to NICE by the company in August 2019, the appraisal of Nivolumab in combination with platinum-doublet chemotherapy for untreated non-small-cell lung cancer [ID1135] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
08 August 2019 Suspended. The National Institute for Health and Clinical Excellence (NICE) has been invited to carry out an appraisal of nivolumab in combination with platinum-doublet chemotherapy for untreated non-small-cell lung cancer. We have recently invited stakeholders to respond to a written consultation on the draft scope which closed on 8 August 2019. The company developing nivolumab, Bristol-Myers Squibb, has advised NICE that they are unable to provide an evidence submission within the scheduled timelines. In light of this information NICE will be suspending this appraisal. If you have any comments or concerns please contact the Project Manager for this appraisal Kate Moore on TACommD@nice.org.uk
18 July 2019 Draft scope documents
11 September 2017 - 09 October 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
12 September 2017 In progress. In progress

For further information on our processes and methods, please see our CHTE processes and methods manual